BioVie Inc. announced on September 23, 2024, its intention to conduct a best efforts public offering of common stock and/or pre-funded warrants, along with accompanying common stock purchase warrants. The company plans to use the net proceeds from this offering primarily for working capital and general corporate purposes.
The offering is subject to market conditions, and there is no assurance regarding its completion, actual size, or specific terms. ThinkEquity is acting as the sole placement agent for this proposed offering.
This move indicates BioVie's ongoing need for external financing to support its clinical-stage drug development programs in neurodegenerative disorders and advanced liver disease.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.